iSign Solutions (ISGN) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 15, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	iSign Solutions Inc.
Entity Central Index Key	727,634
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,761,980

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets Unaudited - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 125	$ 389
Accounts receivable, net of allowance of $45 at March 31, 2017 and $63 at December 31, 2016, respectively	18	137
Prepaid expenses and other current assets	51	56
Total current assets	194	582
Property and equipment, net	16	20
Intangible assets, net	188	269
Other assets	17	17
Total assets	415	888
Current liabilities:
Accounts payable	1,352	1,368
Accrued compensation	247	257
Other accrued liabilities	608	505
Deferred revenue	320	258
Short-term capital lease	4	4
Total current liabilities	2,531	2,392
Long-term debt, net	731	707
Deferred revenue long-term	280	315
Long-term capital lease	8	9
Other long-term liabilities	7	13
Total liabilities	3,557	3,436
Commitments and contingencies
Equity (deficit):
Common stock, $0.01 par value; 2,000,000 shares authorized; 5,760 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	58	58
Treasury shares, 5 at March 31, 2017 and December 31, 2016, respectively	(325)	(325)
Additional paid in capital	128,904	128,884
Accumulated deficit	(131,229)	(130,615)
Accumulated other comprehensive loss	(14)	(14)
Total iSign stockholders' deficit	(2,606)	(2,012)
Non-controlling interest	(536)	(536)
Total deficit	(3,142)	(2,548)
Total liabilities and deficit	$ 415	$ 888

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Jan. 21, 2016
Accounts receivable, net of allowance	$ 45	$ 63
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000,000	2,000,000
Common stock, shares issued	5,760,000	5,760	187,000
Common stock, shares outstanding	5,760,000	5,760	187,000
Treasury shares	5,000	5,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Product	$ 48	$ 59
Maintenance	163	217
Total revenue	211	276
Cost of sales:
Product	4	37
Maintenance	45	133
Research and development	284	318
Sales and marketing	58	202
General and administrative	389	730
Total operating costs and expenses	780	1,420
Loss from operations	(569)	(1,144)
Other income (expense), net		4
Interest expense:
Related party	(6)	(51)
Other	(15)	(60)
Amortization of debt discount:
Related party	(7)	(22)
Other	(17)	(84)
Gain on derivative liability		25
Net loss	(614)	(1,332)
Accretion of beneficial conversion feature, preferred stock:
Related party		(115)
Other		(130)
Preferred stock dividends:
Related party		(420)
Other		(434)
Income tax expense
Net loss attributable to common stockholders	$ (614)	$ (2,431)
Basic and diluted net loss per common share	$ (0.11)	$ (13)
Weighted average common shares outstanding, basic and diluted	5,762	187

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows Unaudited - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (614)	$ (1,332)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	86	91
Stock-based compensation	21	65
Amortization of debt discount	24	106
Gain on derivative liability		(25)
Changes in operating assets and liabilities:
Accounts receivable, net	119	33
Prepaid expenses and other assets	5	19
Accounts payable	(16)	292
Accrued compensation	(10)	6
Other accrued and long-term liabilities	96	212
Deferred revenue	27
Net cash used in operating activities	(262)	(533)
Cash flows from investing activities:
Acquisition of property and equipment	(2)
Net cash used in investing activities	(2)
Cash flows from financing activities:
Proceeds from issuance of short-term debt	120
Payment on short term debt	(120)
Net cash provided by financing activities
Net decrease in cash and cash equivalents	(264)	(533)
Cash and cash equivalents at beginning of period	389	846
Cash and cash equivalents at end of period	125	313
Supplementary disclosure of cash flow information
Interest paid	6	1
Income taxes paid
Non-cash financing and investing transactions:
Dividends on Preferred Stock		854
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends		$ 245

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Nature of Business and Summary of Significant Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	1. Nature of Business and Summary of Significant Accounting Policies Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign’s platform can be deployed both on premise and as a cloud-based (“SaaS”) service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company’s products include SignatureOne® Ceremony™ Server, the iSign® suite of products and services, including iSign® Enterprise and iSign® Console™, and Sign-it® programs. Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2016. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2017 the Company’s accumulated deficit was $131,229. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2017, the Company’s cash balance was $125. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Updates issued in 2017 to date are not applicable to the Company, therefore implementation would not be expected to have a material impact on the Company’s financial position, results of operations and cash flows.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2017
Concentrations [Abstract]
Concentrations	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue 2017 2016 2017 2016 Customer #1 − − 15 % 15 % Customer #2 34 % 33 % − − Customer #3 47 % 63 % 10 % − Customer #4 − − 17 % 13 % Customer #5 − − 12 % 13 % Customer #6 11 % − − − Total concentration 92 % 96 % 54 % 41 %

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2017
Intangible Assets, Net [Abstract]
Intangible Assets, Net	3. Intangible Assets, Net The Company performs an intangible asset impairment analysis at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. Management completed an analysis of the Company’s technology as of December 31, 2016. Based on that analysis, the Company concluded that no impairment of the carrying value of the intangible assets existed. The Company believes that no events or circumstances changed during the three months ended March 31, 2017 that would impact this conclusion. Amortization of intangible asset costs was $81 for the three months ended March 31, 2017 and 2016. The following table summarizes the intangible assets balance: March 31, 2017 December 31, 2016 Carrying Amount Accumulated Amortization Net Value Carrying Amount Accumulative Amortization Net Value Technology $ 6,745 $ (6,557 ) $ 188 $ 6,745 $ (6,476 ) $ 269

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2017
Net Loss Per Share [Abstract]
Net Loss Per Share	4. Net Loss Per Share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted net income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. All of the Company’s preferred shares were converted to common stock on May 19, 2016. The following table lists shares and warrants that were excluded from the calculation of diluted earnings per share as the inclusion of shares from the assumed exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive: For the Three Months Ended March 31, 2017 March 31, 2016 Stock options 71 75 Warrants 1,878 206 Preferred shares as if converted Series A-1 Preferred Stock ─ 50 Series B Preferred Stock ─ 1,069 Series C Preferred Stock ─ 579 Series D-1 Preferred Stock ─ 1,144 Series D-2 Preferred Stock ─ 763

Debt

Debt	3 Months Ended
	Mar. 31, 2017
Debt [Abstract]
Debt	5. Debt Advances: In February 2017, the Company received, from investors and affiliates of the Company, advances aggregating $120 in cash against certain accounts receivable of the Company. Upon collection of an invoice, the Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee. The Company used the funds received from the above advances for working capital and general corporate purposes. The receivables were collected and the advances were repaid in March 2017, along with $6 in advance fees per the agreement. The advance fees were recorded as interest expense in the quarter ended March 31, 2017. Notes payable: In November 2016, the Company issued long-term unsecured convertible promissory notes to investors and affiliates of the Company aggregating $700 in cash. The Company also issued the same long-term notes to affiliates in exchange for an aggregate of $200 in demand notes that had been issued earlier in September and October of 2016. The long-term notes are mandatorily convertible into Common Stock at a conversion rate of the lesser of $1.30 per share or the price per share of Common Stock, upon closing a new debt and or equity financing of at least $1,000 in aggregate proceeds. The notes bear interest at the rate of 6% per annum and are due December 31, 2018. The Company issued warrants to purchase 277 shares of Common Stock in connection with these long-term notes. The Company ascribed a value of $204 to the 277 warrants and recorded a discount to the long-term notes and a corresponding amount to additional paid-in capital. The discount is being amortized using the effective interest method over the term of the notes. The Company used the funds received from the above financings for working capital and general corporate purposes. The Company recorded $24 in debt discount amortization for the three months ended March 31, 2017 related to the above 2016 debt financings.

Equity (Deficit)

Equity (Deficit)	3 Months Ended
	Mar. 31, 2017
Equity (Deficit) [Abstract]
Stockholders' equity (deficit)	6. Equity (Deficit) Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended March 31, 2017 and 2016 was approximately 12.34% and 11.89%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. There were no stock options granted, and no stock options exercised during the three months ended March 31, 2017 and 2016, respectively. The following table summarizes the allocation of stock-based compensation expense for the three months ended March 31: 2017 2016 Research and development $ 8 $ 19 Sales and marketing ─ 14 General and administrative 10 24 Director 3 8 Total stock-based compensation $ 21 $ 65 A summary of option activity under the Company’s plans for the three months ended March 31, 2017 and 2016 is as follows: 2017 2016 Options Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1 71 $ 45.21 82 $ 45.35 Granted − $ − − $ − Forfeited or expired − $ − (7 ) $ 40.51 Outstanding at March 31 71 $ 45.21 2.91 $ − 75 $ 45.84 3.86 $ − Vested and expected to vest at March 31 70 $ 45.53 2.88 $ − 72 $ 46.42 3.80 $ − Exercisable at March 31 62 $ 48.02 2.63 $ − 59 $ 52.16 3.21 $ − The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2017: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $25.00 – $625.00 71 2.91 $ 45.21 62 $ 48.02 A summary of the status of the Company’s non-vested shares as of March 31, 2017 is as follows: Non-vested Shares Shares Weighted Average Non-vested at January 1, 2017 11 $ 23.01 Vested (2 ) $ 22.91 Non-vested at March 31, 2017 9 $ 22.88 As of March 31, 2017, there was $31 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of twelve months. Warrants A summary of the warrant activity for the three months ended March 31 is as follows: 2017 2016 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding at beginning of period 1,882 $ 2.52 206 $ 28.70 Issued ─ $ ─ ─ $ ─ Expired/Canceled (4 ) $ 34.38 ─ $ ─ Outstanding at end of period 1,878 $ 2.69 206 $ 28.70 Exercisable at end of period 1,878 $ 2.69 206 $ 28.70 A summary of the status of the warrants outstanding and exercisable as of March 31, 2017 is as follows: Number of Warrants Weighted Average Weighted Average 50 0.03 $ 15.63 1,551 3.45 $ 2.18 277 0.42 $ 1.63 1,878 2.92 $ 2.69

Nature of Business and Summar12

Nature of Business and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Nature of Business and Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2016. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year.
Going Concern	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2017 the Company’s accumulated deficit was $131,229. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2017, the Company’s cash balance was $125. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accounting Changes and Recent Accounting Pronouncements	Accounting Changes and Recent Accounting Pronouncements Accounting Standards Updates issued in 2017 to date are not applicable to the Company, therefore implementation would not be expected to have a material impact on the Company’s financial position, results of operations and cash flows.

Concentrations (Tables)

Concentrations (Tables)	3 Months Ended
	Mar. 31, 2017
Concentrations [Abstract]
Schedule of accounts receivable and revenue concentrations	Accounts Receivable Total Revenue 2017 2016 2017 2016 Customer #1 − − 15 % 15 % Customer #2 34 % 33 % − − Customer #3 47 % 63 % 10 % − Customer #4 − − 17 % 13 % Customer #5 − − 12 % 13 % Customer #6 11 % − − − Total concentration 92 % 96 % 54 % 41 %

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2017
Intangible Assets, Net [Abstract]
Summary of intangible assets	March 31, 2017 December 31, 2016 Carrying Amount Accumulated Amortization Net Value Carrying Amount Accumulative Amortization Net Value Technology $ 6,745 $ (6,557 ) $ 188 $ 6,745 $ (6,476 ) $ 269

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Net Loss Per Share [Abstract]
Schedule of antidilutive securities excluded from calculation of earnings per share	For the Three Months Ended March 31, 2017 March 31, 2016 Stock options 71 75 Warrants 1,878 206 Preferred shares as if converted Series A-1 Preferred Stock ─ 50 Series B Preferred Stock ─ 1,069 Series C Preferred Stock ─ 579 Series D-1 Preferred Stock ─ 1,144 Series D-2 Preferred Stock ─ 763

Equity (Deficit) (Tables)

Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2017
Equity (Deficit) [Abstract]
Summary of stock compensation plans	2017 2016 Research and development $ 8 $ 19 Sales and marketing ─ 14 General and administrative 10 24 Director 3 8 Total stock-based compensation $ 21 $ 65
Summary of option activity	2017 2016 Options Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1 71 $ 45.21 82 $ 45.35 Granted − $ − − $ − Forfeited or expired − $ − (7 ) $ 40.51 Outstanding at March 31 71 $ 45.21 2.91 $ − 75 $ 45.84 3.86 $ − Vested and expected to vest at March 31 70 $ 45.53 2.88 $ − 72 $ 46.42 3.80 $ − Exercisable at March 31 62 $ 48.02 2.63 $ − 59 $ 52.16 3.21 $ −
Summary of significant ranges of outstanding and exercisable options	Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $25.00 – $625.00 71 2.91 $ 45.21 62 $ 48.02
Summary of status of the Company's non-vested shares	Non-vested Shares Shares Weighted Average Non-vested at January 1, 2017 11 $ 23.01 Vested (2 ) $ 22.91 Non-vested at March 31, 2017 9 $ 22.88
Summary of the warrant activity	2017 2016 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding at beginning of period 1,882 $ 2.52 206 $ 28.70 Issued ─ $ ─ ─ $ ─ Expired/Canceled (4 ) $ 34.38 ─ $ ─ Outstanding at end of period 1,878 $ 2.69 206 $ 28.70 Exercisable at end of period 1,878 $ 2.69 206 $ 28.70
Schedule of warrants outstanding and exercisable	Number of Warrants Weighted Average Weighted Average 50 0.03 $ 15.63 1,551 3.45 $ 2.18 277 0.42 $ 1.63 1,878 2.92 $ 2.69

Nature of Business and Summar17

Nature of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Nature of Business and Summary of Significant Accounting Policies (Textual)
Accumulated deficit	$ (131,229)	$ (130,615)
Cash balance	$ 125	$ 389	$ 313	$ 846

Concentrations (Details)

Concentrations (Details)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accounts Receivable [Member]
Concentration Risk [Line Items]
Total concentration	92.00%	96.00%
Accounts Receivable [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration	34.00%	33.00%
Accounts Receivable [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration	47.00%	63.00%
Accounts Receivable [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #6 [Member]
Concentration Risk [Line Items]
Total concentration	11.00%
Total Revenue [Member]
Concentration Risk [Line Items]
Total concentration	54.00%	41.00%
Total Revenue [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration	15.00%	15.00%
Total Revenue [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration
Total Revenue [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration	10.00%
Total Revenue [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration	17.00%	13.00%
Total Revenue [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration	12.00%	13.00%
Total Revenue [Member] | Customer #6 [Member]
Concentration Risk [Line Items]
Total concentration

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Net Value	$ 188	$ 269
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Carrying Amount	6,745	6,745
Accumulated Amortization	(6,557)	(6,476)
Net Value	$ 188	$ 269

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Intangible Assets, Net [Abstract]
Amortization of intangible asset costs	$ 81	$ 81

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares	71	75
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares	1,878	206
Series A-1 Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares		50
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares		1,069
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares		579
Series D-1 Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares		1,144
Series D-2 Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-diluted earnings per share of options and warrants shares		763

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended
	Feb. 28, 2017	Nov. 30, 2016	Oct. 31, 2016	Sep. 30, 2016	Mar. 31, 2017
Debt [Member]
Short-term Debt [Line Items]
Aggregating amount of debt	$ 120
Advance fees					$ 6
Description of advance fee	The Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee.
Unsecured convertible promissory notes [Member] | Investors and Affiliates [Member]
Short-term Debt [Line Items]
Proceeds from issuance of long-term debt		$ 700
Demand promissory notes [Member] | Investors and Affiliates [Member]
Short-term Debt [Line Items]
Exchange of demand notes for long-term unsecured convertible notes			$ 200	$ 200
Notes Payable [Member]
Short-term Debt [Line Items]
Conversion price		$ 1.30
Proceeds of equity financing		$ 1,000
Interest rate		6.00%
Due date		Dec. 31, 2018
Debt discount amortization					$ 24
Issuance of warrants, Shares		277
Issuance of warrants, Value		$ 204

Equity (Deficit) (Details)

Equity (Deficit) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 21	$ 65
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	8	19
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation		14
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	10	24
Director [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 3	$ 8

Equity (Deficit) (Details 1)

Equity (Deficit) (Details 1) - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Equity (Deficit) [Abstract]
Options Outstanding, Beginning balance	71	82
Options, Granted
Options, Forfeited or expired		(7)
Options Outstanding, Ending balance	71	75
Options, Vested and expected to vest	70	72
Options, Exercisable	62	59
Weighted Average Exercise Price, Beginning balance	$ 45.21	$ 45.35
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Forfeited or expired		40.51
Weighted Average Exercise Price, Ending balance	45.21	45.84
Weighted Average Exercise Price Per Share, Vested and expected to vest	45.53	46.42
Weighted Average Exercise Price Per Share, Exercisable	$ 48.02	$ 52.16
Aggregate Intrinsic Value, Beginning balance
Aggregate Intrinsic Value, Ending balance
Aggregate Intrinsic Value, Vested and expected to vest
Aggregate Intrinsic Value, Exercisable
Weighted Average Remaining Contractual Life, Outstanding	2 years 10 months 28 days	3 years 10 months 10 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	2 years 10 months 17 days	3 years 9 months 18 days
Weighted Average Remaining Contractual Term (Years), Exercisable	2 years 7 months 17 days	3 years 2 months 16 days

Equity (Deficit) (Details 2)

Equity (Deficit) (Details 2) shares in Thousands	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Outstanding and Exercisable options
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	7 years
$25.00 - $625.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	$ 25
Exercise Price Range, Upper Range Limit	$ 625
Outstanding and Exercisable options
Number of Options Outstanding | shares	71
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	2 years 10 months 28 days
Options Outstanding, Weighted Average Exercise Price	$ 45.21
Options Exercisable, Number Outstanding | shares	62
Options Exercisable, Weighted Average Exercise Price	$ 48.02

Equity (Deficit) (Details 3)

Equity (Deficit) (Details 3) shares in Thousands	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Equity Instruments, Options, Nonvested Shares Roll-Forward
Non-vested shares, Beginning | shares	11
Non-vested shares, Vested | shares	(2)
Non-vested shares, Ending | shares	9
Weighted Average Grant Date Fair Value, Beginning | $ / shares	$ 23.01
Weighted Average Grant Date Fair Value, Vested | $ / shares	22.91
Weighted Average Grant Date Fair Value, Ending | $ / shares	$ 22.88

Equity (Deficit) (Details 4)

Equity (Deficit) (Details 4) - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Class Of Warrant Or Right Number Of Warrants Or Rights Roll Forward
Number of Warrants Outstanding at beginning of period	1,882	206
Number of warrants, Expired/Cancelled	(4,000)
Number of Warrants Outstanding at end of period	1,878	206
Number of Warrants, Exercisable at end of period	1,878,000	206,000
Excercise Price of Warrants Outstanding at beginning of period	$ 2.52	$ 28.70
Weighted Average Exercise Price, Issued
Weighted Average Exercise Price, Expired/Cancelled	34.38
Excercise Price of Warrants Outstanding at end of period	2.69	28.70
Weighted Average Exercise Price, Exercisable at end of period	$ 2.69	$ 28.70

Equity (Deficit) (Details 5)

Equity (Deficit) (Details 5) - $ / shares	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	1,878	1,882	206	206
Weighted Average Remaining Life	2 years 11 months 1 day
Weighted Average Exercise Price per share	$ 2.69
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	50
Weighted Average Remaining Life	11 days
Weighted Average Exercise Price per share	$ 15.63
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	1,551
Weighted Average Remaining Life	3 years 5 months 12 days
Weighted Average Exercise Price per share	$ 2.18
Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	277
Weighted Average Remaining Life	5 months 1 day
Weighted Average Exercise Price per share	$ 1.63

Equity (Deficit) (Details Textu

Equity (Deficit) (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Equity (Deficit) (Textual)
Estimated average forfeiture rate	12.34%	11.89%
Total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans	$ 31
Unrecognized compensation expense amortization period	12 months